The FDA’s new draft guidance clarifies how drug developers can validate and use non-animal testing methods, reducing regulatory uncertainty and accelerating adoption of human-relevant…
Novartis used PBPK modeling for therapeutic regulatory success. They used model simulations to replace clinical studies, predict DDIs, and support asciminib’s approval.
